TABLE OF CONTENTS
1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW OF THE EUROPE RADIOPHARMACEUTICALS MARKET 31
1.4 LIMITATIONS 33
1.5 MARKETS COVERED 33
2 MARKET SEGMENTATION 35
2.1 MARKETS COVERED 35
2.2 GEOGRAPHICAL SCOPE 36
2.3 YEARS CONSIDERED FOR THE STUDY 36
2.4 CURRENCY AND PRICING 36
2.5 DBMR TRIPOD DATA VALIDATION MODEL 37
2.6 MULTIVARIATE MODELLING 40
2.7 TYPE LIFELINE CURVE 40
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 41
2.9 DBMR MARKET POSITION GRID 42
2.10 MARKET TESTING TYPE COVERAGE GRID 44
2.11 SECONDARY SOURCES 45
2.12 ASSUMPTIONS 45
3 EXECUTIVE SUMMARY 46
4 PREMIUM INSIGHTS 49
4.1 PESTEL ANALYSIS 50
4.2 PORTERS FIVE FORCES 51
4.3 PIPELINE ANALYSIS 52
4.4 PATENT ANALYSIS 53
4.5 DRUG TREATMENT RATE BY MATURED MARKETS 59
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 60
4.7 PATIENT FLOW DIAGRAM 61
4.8 KEY PRICING STRATEGIES 61
4.9 KEY PATIENT ENROLLMENT STRATEGIES 62
5 LIST OF CYCLOTRONS 64
5.1 EUROPE 64
6 REGULATORY SCENARIO 75
6.1 EUROPE 75
7 MARKET OVERVIEW 76
7.1 DRIVERS 78
7.1.1 THE GROWING DEMAND FOR RADIOPHARMACEUTICALS IN DIAGNOSTICS AND CLINICAL USE 78
7.1.2 THE INCREASING NEED FOR PHARMACEUTICAL PRODUCTS ACROSS VARIED THERAPEUTIC AREAS 78
7.1.3 THE INCREASING PREVALENCE OF CHRONIC DISEASES 79
7.2 RESTRAINTS 79
7.2.1 STRINGENT REGULATIONS FOR RADIOPHARMACEUTICALS 79
7.2.2 POTENTIAL RISKS ASSOCIATED WITH RADIOPHARMACEUTICALS 79
7.3 OPPORTUNITIES 80
7.3.1 THE RISING RESEARCH AND DEVELOPMENT EXPENDITURE OF RADIOPHARMACEUTICALS 80
7.3.2 THE GROWING INCIDENCES OF COMPLEX DISEASES IN GERIATRIC POPULATION 80
7.4 CHALLENGES 81
7.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS 81
7.4.2 LACK OF TECHNICAL EXPERTISE AND HIGH COST FOR TRAINING EXISTING WORKFORCE 82
8 EUROPE RADIOPHARMACEUTICALS MARKET, BY TYPE 83
8.1 OVERVIEW 84
8.2 DIAGNOSTIC RADIOPHARMACEUTICALS 87
8.2.1 PET RADIOPHARMACEUTICALS 88
8.2.1.1 F-18 88
8.2.1.2 RU-82 88
8.2.1.3 OTHER PET ISOTOPES RADIOPHARMACEUTICALS 88
8.2.2 SPECT RADIOPHARMACEUTICALS 89
8.2.2.1 TECHNETIUM-99M 89
8.2.2.2 GALLIUM-67 89
8.2.2.3 IODINE-123 89
8.2.2.4 THALLIUM-201 89
8.2.2.5 OTHER SPECT ISOTOPES 89
8.3 THERAPEUTIC RADIOPHARMACEUTICALS 89
8.3.1 BRACHYTHERAPY ISOTOPES 90
8.3.1.1 IODINE-125 91
8.3.1.2 PALLADIUM-103 91
8.3.1.3 CESIUM-131 91
8.3.1.4 IRIDIUM-192 91
8.3.1.5 OTHER BRACHYTHERAPY ISOTOPES 91
8.3.2 BETA EMITTERS 91
8.3.2.1 IODINE-131 92
8.3.2.2 LUTHETIUM-177 92
8.3.2.3 SAMARIUM-153 92
8.3.2.4 YTTRIUM-90 92
8.3.2.5 RHENIUM-186 92
8.3.2.6 OTHER BETA EMITTERS 92
8.3.3 ALPHA EMITTERS 92
8.3.3.1 RA-223 93
8.3.3.2 OTHERS 93
9 EUROPE RADIOPHARMACEUTICALS MARKET, BY APPLICATION 94
9.1 OVERVIEW 95
9.2 DIAGNOSTIC 98
9.2.1 PET 99
9.2.1.1 ONCOLOGY 99
9.2.1.2 CARDIOLOGY 99
9.2.1.3 NEUROLOGY 99
9.2.1.4 OTHER PET APPLICATION 99
9.2.2 SPECT 100
9.2.2.1 CARDIOLOGY 100
9.2.2.2 BONE SCANS 100
9.2.2.3 THYROID APPLICATIONS 100
9.2.2.4 PULMONARY SCANS 100
9.2.2.5 OTHER SPECT APPLICATION 100
9.3 THERAPEUTIC 101
9.3.1 THYROID INDICATIONS 101
9.3.2 BONE METASTASIS 101
9.3.3 LYMPHOMA 102
9.3.4 ENDOCRINE TUMORS 102
9.3.5 OTHER INDICATIONS 102
10 EUROPE RADIOPHARMACEUTICALS MARKET, BY SOURCE 103
10.1 OVERVIEW 104
10.2 NUCLEAR REACTORS 107
10.3 CYCLOTRONS 107
11 EUROPE RADIOPHARMACEUTICALS MARKET, BY END USER 108
11.1 OVERVIEW 109
11.2 HOSPITALS 112
11.3 DIAGNOSTIC CENTERS 112
11.4 CANCER RESEARCH INSTITUTES 112
11.5 AMBULATORY SURGICAL CENTERS 113
11.6 OTHERS 113
12 EUROPE RADIOPHARMACEUTICAL MARKET 114
12.1 EUROPE 114
12.1.1 GERMANY 125
12.1.2 U.K. 132
12.1.3 FRANCE 139
12.1.4 ITALY 146
12.1.5 SPAIN 153
12.1.6 BELGIUM 160
12.1.7 POLAND 167
12.1.8 RUSSIA 174
12.1.9 NORWAY 181
12.1.10 TURKEY 188
12.1.11 AUSTRIA 194
12.1.12 IRELAND 201
12.1.13 HUNGARY 208
12.1.14 NETHERLANDS 215
12.1.15 SWITZERLAND 222
12.1.16 REST OF EUROPE 229
13 COMPANY LANDSCAPE 230
13.1 COMPANY SHARE ANALYSIS: EUROPE 230
14 SWOT ANALYSIS 231
15 COMPANY PROFILE 232
15.1 CARDINAL HEALTH 232
15.1.1 COMPANY SNAPSHOT 232
15.1.2 REVENUE ANALYSIS 232
15.1.3 COMPANY SHARE ANALYSIS 233
15.1.4 PRODUCT PORTFOLIO 233
15.1.5 RECENT DEVELOPMENT 234
15.2 ADVANCED ACCELERATOR APPLICATIONS, A NOVARTIS COMPANY 235
15.2.1 COMPANY SNAPSHOT 235
15.2.2 REVENUE ANALYSIS 235
15.2.3 COMPANY SHARE ANALYSIS 236
15.2.4 PRODUCT PORTFOLIO 236
15.2.5 RECENT DEVELOPMENT 236
15.3 LANTHEUS 237
15.3.1 COMPANY SNAPSHOT 237
15.3.2 REVENUE ANALYSIS 237
15.3.3 COMPANY SHARE ANALYSIS 238
15.3.4 PRODUCT PORTFOLIO 238
15.3.5 RECENT DEVELOPMENT 238
15.4 CURIUM 239
15.4.1 COMPANY SNAPSHOT 239
15.4.2 COMPANY SHARE ANALYSIS 239
15.4.3 PRODUCT PORTFOLIO 240
15.4.4 RECENT DEVELOPMENT 240
15.5 GENERAL ELECTRIC COMPANY 241
15.5.1 COMPANY SNAPSHOT 241
15.5.2 REVENUE ANALYSIS 241
15.5.3 COMPANY SHARE ANALYSIS 242
15.5.4 PRODUCT PORTFOLIO 242
15.5.5 RECENT DEVELOPMENT 242
15.6 BRACCO 243
15.6.1 COMPANY SNAPSHOT 243
15.6.2 PRODUCT PORTFOLIO 243
15.6.3 RECENT DEVELOPMENT 243
15.7 CHINA ISOTOPE & RADIATION CORPORATION 244
15.7.1 COMPANY SNAPSHOT 244
15.7.2 REVENUE ANALYSIS 244
15.7.3 PRODUCT PORTFOLIO 245
15.7.4 RECENT DEVELOPMENT 245
15.8 ECKERT & ZIEGLER 246
15.8.1 COMPANY SNAPSHOT 246
15.8.2 REVENUE ANALYSIS 246
15.8.3 PRODUCT PORTFOLIO 247
15.8.4 RECENT DEVELOPMENT 247
15.9 IBA WORLDWIDE 248
15.9.1 COMPANY SNAPSHOT 248
15.9.2 REVENUE ANALYSIS 248
15.9.3 PRODUCT PORTFOLIO 249
15.9.4 RECENT DEVELOPMENT 249
15.10 INSTITUTE OF ISOTOPES 250
15.10.1 COMPANY SNAPSHOT 250
15.10.2 PRODUCT PORTFOLIO 250
15.10.3 RECENT DEVELOPMENT 250
15.11 JUBILANT RADIOPHARMA A JUBILANT PHARMOVA COMPANY 251
15.11.1 COMPANY SNAPSHOT 251
15.11.2 REVENUE ANALYSIS 251
15.11.3 PRODUCT PORTFOLIO 252
15.11.4 RECENT DEVELOPMENT 252
15.12 SHINE TECHNOLOGIES, LLC 253
15.12.1 COMPANY SNAPSHOT 253
15.12.2 PRODUCT PORTFOLIO 253
15.12.3 RECENT DEVELOPMENT 253
15.13 SIEMENS HEALTHCARE GMBH 254
15.13.1 COMPANY SNAPSHOT 254
15.13.2 REVENUE ANALYSIS 254
15.13.3 PRODUCT PORTFOLIO 255
15.13.4 RECENT DEVELOPMENT 255
16 QUESTIONNAIRE 256
17 RELATED REPORTS 259

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.